IP-10 and MCP-1 gene polymorphisms in Chinese patients with chronic immune thrombocytopenia

References

• Semple JW. Infections, antigen-presenting cells, T cells, and immune tolerance: their role in the pathogenesis of immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23(6):1177–1192.
   PubMed Web of Science ®Google Scholar
• Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123–1124.
   PubMed Web of Science ®Google Scholar
• Mouzaki A, Theodoropoulou M, Gianakopoulos I, et al. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood. 2002;100(5):1774–1779.
   PubMed Web of Science ®Google Scholar
• Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87(10):4245–4254.
   PubMed Web of Science ®Google Scholar
• Ogawara H, Handa H, Morita K, et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;71(4):283–288.
   PubMed Web of Science ®Google Scholar
• Melik-Parsadaniantz S, Rostene W. Chemokines and neuromodulation. J Neuroimmunol. 2008;198:62–68.
   PubMed Web of Science ®Google Scholar
• Nakajima H, Fukuda K, Doi Y, et al. Expression of TH1/TH2-related chemokine receptors on peripheral T cells and correlation with clinical disease activity in patients with multiple sclerosis. Eur Neurol. 2004;52(3):162–168.
   PubMed Web of Science ®Google Scholar
• Dufour JH, Dziejman M, Liu MT, et al. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol. 2002;168(7):3195–3204.
   PubMed Web of Science ®Google Scholar
• Liu L, Callahan MK, Huang D, et al. Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol. 2005;68:149–181.
   PubMed Web of Science ®Google Scholar
• Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev. 2009;8(5):379–383.
   PubMed Web of Science ®Google Scholar
• Nakajima H, Kobayashi M, Pollard RB, et al. Monocyte chemoattractant protein-1 enhances HSV-induced encephalomyelitis by stimulating Th2 responses. J Leukoc Biol. 2001;70(3):374–380.
   PubMed Web of Science ®Google Scholar
• Deng G, Zhou G, Zhang R, et al. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology. 2008;134(3):716–726.
   PubMed Web of Science ®Google Scholar
• Pola R, Flex A, Gaetani E, et al. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer's disease in Italians. Exp Gerontol. 2004;39(8):1249–1252.
   PubMed Web of Science ®Google Scholar
• Steinmetz OM, Panzer U, Harendza S, et al. No association of the -2518 MCP-1 A/G promoter polymorphism with incidence and clinical course of IgA nephropathy. Nephrol Dial Transplant. 2004;19(3):596–601.
   PubMed Web of Science ®Google Scholar
• Gu D, Chen Z, Zhao H, et al. Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia. Hum Immunol. 2010;71(6):586–591.
   PubMed Web of Science ®Google Scholar
• Panitsas FP, Theodoropoulou M, Kouraklis A, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004;103(7):2645–2647.
   PubMed Web of Science ®Google Scholar
• Yazdanbakhsh K, Zhong H, Bao W. Immune dysregulation in immune thrombocytopenia. Semin Hematol. 2013;50(1):S63–S67.
   PubMedGoogle Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393.
   PubMed Web of Science ®Google Scholar
• Wang T, Zhao H, Ren H, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica. 2005;90(7):914–923.
   PubMed Web of Science ®Google Scholar
• Di Domenicantonio A. Rheumatoid arthritis and the alpha-chemokine IP-10. Clin Ter. 2014;165(6):e447–451.
   PubMedGoogle Scholar
• Rose T, Grutzkau A, Hirseland H, et al. IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2013;72(10):1639–1645.
   PubMed Web of Science ®Google Scholar
• Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103(6):807–815.
   PubMed Web of Science ®Google Scholar
• Sorensen TL. Targeting the chemokine receptor CXCR3 and its ligand CXCL10 in the central nervous system: potential therapy for inflammatory demyelinating disease? Curr Neurovasc Res. 2004;1(2):183–190.
   PubMed Web of Science ®Google Scholar
• Ruffilli I, Ferrari SM, Colaci M, et al. IP-10 in autoimmune thyroiditis. Horm Metab Res. 2014;46(9):597–602.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Rotondi M, et al. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol. 2006;154(5):651–658.
   PubMed Web of Science ®Google Scholar
• Strieter RM, Kunkel SL, Arenberg DA, et al. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun. 1995;210(1):51–57.
   PubMed Web of Science ®Google Scholar
• Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol. 2001;2(2):102–107.
   PubMed Web of Science ®Google Scholar
• Narumi S, Takeuchi T, Kobayashi Y, et al. Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine. 2000;12(10):1561–1565.
   PubMed Web of Science ®Google Scholar
• Nagahama M, Nomura S, Kanazawa S, et al. Significance of chemokines and soluble CD40 ligand in patients with autoimmune thrombocytopenic purpura. Eur J Haematol. 2002;69(5-6):303–308.
   PubMed Web of Science ®Google Scholar
• George JN, Raskob GE. Idiopathic thrombocytopenic purpura: diagnosis and management. Am J Med Sci. 1998;316(2):87–93.
   PubMed Web of Science ®Google Scholar
• Whitacre CC. Sex differences in autoimmune disease. Nat immunol. 2001;2(9):777–780.
   PubMed Web of Science ®Google Scholar
• Axelsson S, Faresjo M, Hedman M, et al. Cryopreserved peripheral blood mononuclear cells are suitable for the assessment of immunological markers in type 1 diabetic children. Cryobiology. 2008;57(3):201–208.
   PubMed Web of Science ®Google Scholar
• Christen U, von Herrath MG. IP-10 and type 1 diabetes: a question of time and location. Autoimmunity. 2004;37(4):273–282.
   Web of Science ®Google Scholar